Topotecan alleviates ventilator-induced lung injury via NF-κB pathway inhibition

被引：12

作者：

Wan, Bing ^{[1
,2
]}

Xu, Wu-jian ^{[1
]}

Zhan, Ping ^{[1
]}

Jin, Jia-jia ^{[1
]}

Xi, Guang-min ^{[1
]}

Chen, Mei-zi ^{[1
]}

Hu, Yang-bo ^{[1
]}

Zhu, Su-hua ^{[1
]}

Liu, Hong-bing ^{[1
]}

Wang, Xiao-xia ^{[1
]}

Zhang, Xiu-wei ^{[2
]}

Lv, Tang-feng ^{[1
]}

Song, Yong ^{[1
]}

机构：

[1] Southern Med Univ Guangzhou, Nanjing Clin Sch, Jinling Hosp, Dept Resp & Crit Med, Nanjing 210002, Jiangsu, Peoples R China

[2] Nanjing Med Univ, Affiliated Jiangning Hosp, Dept Resp Med, Nanjing 210002, Jiangsu, Peoples R China

来源：

CYTOKINE | 2018年 / 110卷

基金：

中国国家自然科学基金;

关键词：

Ventilator-induced lung injury; Topotecan; Nuclear factor-kappa B (NF-kappa B); RESPIRATORY-DISTRESS-SYNDROME; NEUTROPHILIC INFLAMMATION; CANCER; CELLS; MODEL; ACTIVATION; EXPRESSION; ALPHA;

D O I：

10.1016/j.cyto.2018.04.016

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Objective: We investigated the effect of topotecan on injury and inflammation in a model of ventilator-induced lung injury (VILI). Methods: Acute lung injury (ALI) was induced in mice by high-tidal volume ventilation, and the mice were then treated with topotecan or PBS. Lung tissue and bronchoalveolar lavage fluid were collected to assess pulmonary vascular leaks, inflammation, and cell apoptosis. Results: Compared to PBS treatment, topotecan significantly decreased the ALI score, myeloperoxidase (MPO) content, total protein concentration, and presence of inflammatory cells and inflammatory cytokines in bronchoalveolar lavage fluid. Topotecan also reduced caspase-3 activation and type II alveolar epithelial cell apoptosis. Moreover, topotecan inhibited NF-kappa B expression and activation in the VILI model. Conclusion: Topotecan alleviates acute lung injury in the model of VILI through the inhibition of the NF-kappa B pathway.

引用

页码：381 / 388

页数：8

共 37 条

[31] Spoto G, 2016, J BIOL REG HOMEOS AG, V30, P997
[32] The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells
Trojandt, Stefanie
Knies, Diana
Pektor, Stefanie
Ritz, Sandra
Mailaender, Volker
Grabbe, Stephan
Reske-Kunz, Angelika B.
Bros, Matthias
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (08) : 1315 - 1326
[33] Synthetic Lethal Screen Identifies NF-κB as a Target for Combination Therapy with Topotecan for patients with Neuroblastoma
Tsang, Patricia S.
Cheuk, Adam T.
Chen, Qing-Rong
Song, Young K.
Badgett, Thomas C.
Wei, Jun S.
Khan, Javed
[J]. BMC CANCER, 2012, 12
[34] Medical progress - The acute respiratory distress syndrome.
Ware, LB
Matthay, MA
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (18) : 1334 - 1349
[35] Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response
Yeo, Winnie
Chan, Stephen L.
Mo, Frankie K. F.
Chu, Cheuk M.
Hui, Joyce W. Y.
Tong, Joanne H. M.
Chan, Anthony W. H.
Koh, Jane
Hui, Edwin P.
Loong, Herbert
Lee, Kirsty
Li, Leung
Ma, Brigette
To, Ka F.
Yu, Simon C. H.
[J]. BMC CANCER, 2015, 15
[36] Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models
Zhang, Libo
Marrano, Paula
Wu, Bing
Kumar, Sushil
Thorner, Paul
Baruchel, Sylvain
[J]. CLINICAL CANCER RESEARCH, 2016, 22 (11) : 2697 - 2708
[37] HIV Replication in CD4+ T Lymphocytes in the Presence and Absence of Follicular Dendritic Cells: Inhibition of Replication Mediated by α-1-Antitrypsin through Altered IκBα Ubiquitination
Zhou, Xueyuan
Shapiro, Leland
Fellingham, Gilbert
Willardson, Barry M.
Burton, Gregory F.
[J]. JOURNAL OF IMMUNOLOGY, 2011, 186 (05) : 3148 - 3155

← 1 2 3 4 →